Cancer News and Research

Latest Cancer News and Research

ERCC1 Analysis guides patient treatment decisions

Moffitt Cancer Center announces steadily growing interest in the ERCC1 Analysis, the first test developed for selecting chemotherapy for Non Small Lung Cancer patients. Each year, more than 200,000 Americans are diagnosed with lung cancer.

26 Apr 2010

Today's opinions: Health overhaul reflects history of government intervention; Importance of repairing clinical trials system; Stopping Medicare fraud

The system's opacity gives insurers the upper hand in debates over government payment rates (Austin Frakt, 4/26).

26 Apr 2010

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.

26 Apr 2010

The Frost Group agrees to make investment in ChromaDex

ChromaDex Corporation, a natural products chemistry company which provides novel and innovative ingredients to the dietary supplement, food, beverage and cosmetic markets, announced today The Frost Group, LLC, led by Miami entrepreneur and billionaire Dr. Phillip Frost, has agreed to make an investment in ChromaDex.

26 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

OSI Pharmaceuticals, Inc. announced today that it has completed enrollment in the RADIANT study, a Phase III clinical trial testing Tarceva (erlotinib) as an adjuvant therapy in patients with Stage IB-IIIA non-small cell lung cancer who have undergone surgery and have EGFR-positive tumors.

26 Apr 2010

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Ophthotech Corp., a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, today announced that the first patient has been enrolled in its Phase II randomized, controlled clinical trial of E10030, an anti-PDGF aptamer, in combination with Lucentis® for the treatment of wet age-related macular degeneration (AMD).

26 Apr 2010

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

26 Apr 2010

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Veran Medical Technologies announced today that it has recently completed its first installation and performed several procedures at Duke University Medical Center with its FDA-cleared SPiN Drive product. The product enables clinicians to navigate deep into the peripheral regions of the lungs to access, biopsy and treat potentially cancerous Solitary Pulmonary Nodules.

26 Apr 2010

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it has advanced into drug development a discovery research candidate directed against PCSK9 (proprotein convertase subtilisin/kexin type 9), an important new target for the treatment of high cholesterol. Using its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, Santaris Pharma A/S identified and advanced the new drug, SPC5001, in just 18 months.

26 Apr 2010

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Researchers synthesize metal compounds that can be effective in treatment of cancer

Scientists from Bochum have managed to accurately determine the location of metal complexes within living cancer cells using Raman microscopy. The researchers have thus gained new insights into the mechanism of action of metal-containing drugs, to which they ascribe great potential capacities, e.g. in the treatment of cancer.

26 Apr 2010

Bowel cancer screening programme launched in Northern Ireland

The bowel cancer screening programme, which detects early signs of the disease, has been launched in Northern Ireland.

26 Apr 2010

New reprogramming strategies needed for production of iPSCs: Study

Scientists may be one step closer to being able to generate any type of cells and tissues from a patient's own cells. In a study that will appear in the journal Nature and is receiving early online release, investigators from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute (HSCI), describe finding that an important cluster of genes is inactivated in induced pluripotent stem cells (iPSCs) that do not have the full development potential of embryonic stem cells.

26 Apr 2010

Mothers with preeclampsia at reduced risk of developing breast cancer

Preeclampsia is a high blood pressure syndrome in pregnant mothers that is caused when the blood supply in the placenta of the developing baby is restricted. The blood-deprived placenta releases factors that cause the raise in blood pressure in the mother. Doctors have to monitor these women closely and they may be forced to deliver the baby early to protect the mother and the baby. Most women's blood pressure returns to normal levels after they deliver the placenta.

26 Apr 2010

Negotiations break off between TUH and PASNAP

Negotiations broke off early Monday morning between Temple University Hospital and the Pennsylvania Association of Staff Nurses & Allied Professionals after sessions on Saturday and an over 18-hour session Sunday into Monday.

26 Apr 2010

Electronic primary care records can help identify untreated patients at high risk of cardiovascular disease

Using routine data from electronic patient records to select individuals at high risk of developing heart disease, rather than screening all adults aged between 40 and 74 years of age, is just as effective at saving lives but will be cheaper to run, according to research published on bmj.com today.

26 Apr 2010

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cigarette smoking is a major cause of illness and death worldwide. But it is a complex behavior, and how much people smoke, how hard they find it to quit, and the impact of long-term smoking on health varies greatly among individuals. A substantial portion of this variability is genetic. Two years ago, deCODE discovered the first common, single-letter variation in the sequence of the human genome, on chromosome 15q25, associated with nicotine addiction and risk of lung cancer.

26 Apr 2010

Cancer News and Research

Latest Cancer News and Research

ERCC1 Analysis guides patient treatment decisions

Today's opinions: Health overhaul reflects history of government intervention; Importance of repairing clinical trials system; Stopping Medicare fraud

EDAP announces strategy for ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial

The Frost Group agrees to make investment in ChromaDex

Caltech biologists offer new insight into causes of IBD and colon cancer

OSI Pharmaceuticals completes enrollment in Phase III clinical trial of Tarceva

First patient enrolled in Phase II clinical trial of E10030 for treatment of wet age-related AMD

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

Duke University Medical Center installs Veran Medical Technologies' SPiN Drive system

Santaris Pharma advances into drug development SPC5001 research candidate against PCSK9

OICR makes equity investments in three promising Ontario technologies

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Researchers synthesize metal compounds that can be effective in treatment of cancer

Bowel cancer screening programme launched in Northern Ireland

New reprogramming strategies needed for production of iPSCs: Study

Mothers with preeclampsia at reduced risk of developing breast cancer

Negotiations break off between TUH and PASNAP

Electronic primary care records can help identify untreated patients at high risk of cardiovascular disease

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in